Original Article Aldehyde dehydrogenase 1 expression correlates with clinicopathologic features of patients with breast cancer: a meta-analysis

A number of studies have investigated the relationship between aldehyde dehydrogenase 1 (ALDH1) ex- pression and the clinical pathological features of the patients with breast cancer. However, conclusions reported by different parties seem to be inconsistent. We have reviewed published studies and carried out this meta-analysis to provide credible results. We searched PubMed for articles published in English until September 12, 2014. Our main analyses were focused on the association between ALDH1 and the clinical pathological features, such as age, tumor size, nodal status, lymphovascular invasion, histological grade, and the expression of ER, PR, and HER2 by meta-analysis methods. If heterogeneity was observed, we used random effects model to calculate the overall odds ratios, otherwise fixed effects model was used. Twenty-one eligible studies were included in the present meta- analysis. From the pooled analyses, there was significant association between ALDH1 expression and histological grade (low vs. intermediate: pooled OR = 1.51, 95% CI: 1.09-2.10, P = 0.01; intermediate vs. high: pooled OR = 1.86, 95% CI: 1.12-3.07, P = 0.02), ER expression (pooled OR = 0.41, 95% CI: 0.29-0.58, P 0.05). Despite the inconsistency in the published reports, this meta-analysis provides credible evidence to support the association between ALDH1 and breast cancer. However, it is necessary to conduct large sample studies using standardized and well-matched controls.

[1]  W. Woodward,et al.  Aldehyde dehydrogenase 1 expression in inflammatory breast cancer as measured by immunohistochemical staining. , 2014, Clinical breast cancer.

[2]  Chung-Han Lee,et al.  Clinicopathologic Characteristics of Breast Cancer Stem Cells Identified on the Basis of Aldehyde Dehydrogenase 1 Expression , 2014, Journal of breast cancer.

[3]  M. Schneider-Kolsky,et al.  Changes in aldehyde dehydrogenase-1 expression during neoadjuvant chemotherapy predict outcome in locally advanced breast cancer , 2014, Breast Cancer Research.

[4]  Q. Sun,et al.  ALDH1 is a better clinical indicator for relapse of invasive ductal breast cancer than the CD44+/CD24− phenotype , 2014, Medical Oncology.

[5]  O. Woo,et al.  Association of aldehyde dehydrogenase 1 expression and biologically aggressive features in breast cancer. , 2014, Neoplasma.

[6]  S. Noguchi,et al.  Clinicopathological Analysis of Breast Ductal Carcinoma in situ with ALDH1-Positive Cancer Stem Cells , 2013, Oncology.

[7]  J. Akiba,et al.  Aldehyde Dehydrogenase 1 Identifies Cells with Cancer Stem Cell-Like Properties in a Human Renal Cell Carcinoma Cell Line , 2013, PloS one.

[8]  N. Xu,et al.  The expression of aldehyde dehydrogenase 1 in invasive primary breast tumors and axillary lymph node metastases is associated with poor clinical prognosis. , 2013, Pathology, research and practice.

[9]  Q. Sun,et al.  Expression of ALDH1 in breast invasive ductal carcinoma: an independent predictor of early tumor relapse , 2013, Cancer Cell International.

[10]  Wei Zhang,et al.  An associated classification of triple negative breast cancer: the risk of relapse and the response to chemotherapy. , 2013, International journal of clinical and experimental pathology.

[11]  L. Newman,et al.  Expression of aldehyde dehydrogenase 1 as a marker of mammary stem cells in benign and malignant breast lesions of Ghanaian women , 2013, Cancer.

[12]  K. Yao,et al.  Cancer stem cell characteristics, ALDH1 expression in the invasive front of nasopharyngeal carcinoma , 2013, Virchows Archiv.

[13]  M. Miyazaki,et al.  Aldehyde dehydrogenase 1‐positive cells in axillary lymph node metastases after chemotherapy as a prognostic factor in patients with lymph node‐positive breast cancer , 2012, Cancer.

[14]  M. Asadi-lari,et al.  High expression of stem cell marker ALDH1 is associated with reduced BRCA1 in invasive breast carcinomas. , 2012, Asian Pacific journal of cancer prevention : APJCP.

[15]  R. Rocha,et al.  Prognostic impact of the cancer stem cell related markers ALDH1 and EZH2 in triple negative and basal-like breast cancers , 2012, Pathology.

[16]  A. D. de Craen,et al.  Age determines the prognostic role of the cancer stem cell marker aldehyde dehydrogenase-1 in breast cancer , 2012, BMC Cancer.

[17]  Hirokuni Ikeda,et al.  Expression of ALDH1 in axillary lymph node metastases is a prognostic factor of poor clinical outcome in breast cancer patients with 1–3 lymph node metastases , 2012, Breast Cancer.

[18]  A. Tanimoto,et al.  Aldehyde dehydrogenase 1 expression predicts poor prognosis in triple‐negative breast cancer , 2011, Histopathology.

[19]  M. Sabel,et al.  EZH2 and ALDH-1 mark breast epithelium at risk for breast cancer development , 2011, Modern Pathology.

[20]  Jae Hyun Kim,et al.  An increase in cancer stem cell population after primary systemic therapy is a poor prognostic factor in breast cancer , 2011, British Journal of Cancer.

[21]  A. Tanimoto,et al.  Aldehyde dehydrogenase 1 expression is a predictor of poor prognosis in node‐positive breast cancers: a long‐term follow‐up study , 2011, Histopathology.

[22]  Jorge S. Reis-Filho,et al.  Histological types of breast cancer: How special are they? , 2010, Molecular oncology.

[23]  Ling Zhou,et al.  Prognostic relevance of ALDH1 in breast cancer: a clinicopathological study of 96 cases , 2010 .

[24]  L. Akslen,et al.  Expression of aldehyde dehydrogenase 1 (ALDH1) is associated with basal-like markers and features of aggressive tumours in African breast cancer , 2009, British Journal of Cancer.

[25]  J. Reis-Filho,et al.  Prognostic impact of ALDH1 in breast cancer: a story of stem cells and tumor microenvironment , 2010, Breast Cancer Research and Treatment.

[26]  F. Bertucci,et al.  Aldehyde Dehydrogenase 1–Positive Cancer Stem Cells Mediate Metastasis and Poor Clinical Outcome in Inflammatory Breast Cancer , 2009, Clinical Cancer Research.

[27]  David A Hess,et al.  High aldehyde dehydrogenase and expression of cancer stem cell markers selects for breast cancer cells with enhanced malignant and metastatic ability , 2009, Journal of cellular and molecular medicine.

[28]  T. Taguchi,et al.  Stem cell marker aldehyde dehydrogenase 1‐positive breast cancers are characterized by negative estrogen receptor, positive human epidermal growth factor receptor type 2, and high Ki67 expression , 2009, Cancer science.

[29]  Tao Zhang,et al.  Aldehyde dehydrogenase 1 is a marker for normal and malignant human colonic stem cells (SC) and tracks SC overpopulation during colon tumorigenesis. , 2009, Cancer research.

[30]  R. Dhir,et al.  Identification of human aldehyde dehydrogenase 1 family member A1 as a novel CD8+ T-cell-defined tumor antigen in squamous cell carcinoma of the head and neck. , 2007, Cancer research.

[31]  J. Krieger,et al.  Three endothelial nitric oxide (NOS3) gene polymorphisms in hypertensive and normotensive individuals: meta-analysis of 53 studies reveals evidence of publication bias , 2007, Journal of hypertension.